New cancer drug PRO1107 tested in advanced tumors – study halted early
NCT ID NCT06171789
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 34 times
Summary
This study tested a new drug called PRO1107 in 33 people with advanced solid tumors like ovarian, endometrial, and lung cancers. The goal was to check safety and see if the drug could shrink tumors. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Florida Cancer Specialists
Sarasota, Florida, 34236, United States
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
Institution of Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START Mountain Cancer Center
Salt Lake City, Utah, 78229, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.